Switch to: References

Add citations

You must login to add citations.
  1. Beyond Cost‐Benefit Analysis in the Governance of Synthetic Biology.Wendell Wallach, Marc Saner & Gary Marchant - 2018 - Hastings Center Report 48 (S1):70-77.
    For many innovations, oversight fits nicely within existing governance mechanisms; nevertheless, others pose unique public health, environmental, and ethical challenges. Synthetic artemisinin, for example, has many precursors in laboratory‐developed drugs that emulate natural forms of the same drug. The policy challenges posed by synthetic artemisinin do not differ significantly in kind from other laboratory‐formulated drugs. Synthetic biofuels and gene drives, however, fit less clearly into existing governance structures. How many of the new categories of products require new forms of regulatory (...)
    Download  
     
    Export citation  
     
    Bookmark   3 citations  
  • Making Policies about Emerging Technologies.Gregory E. Kaebnick & Michael K. Gusmano - 2018 - Hastings Center Report 48 (S1):2-11.
    Can we make wise policy decisions about still‐emerging technologies—decisions that are grounded in facts yet anticipate unknowns and promote the public's preferences and values? There is a widespread feeling that we should try. There also seems to be widespread agreement that the central element in wise decisions is the assessment of benefits and costs, understood as a process that consists, at least in part, in measuring, tallying, and comparing how different outcomes would affect the public interest. But how benefits and (...)
    Download  
     
    Export citation  
     
    Bookmark   2 citations